Zohar Krivorot

Cannara Biotech Reports 6% YoY Drop In Q3 Gross Profit, 22% Revenue Increase As It Enhances Sales Force And Infrastructure

Cannara Biotech Q3 FY23 Net Revenue Grows 57% YoY, What About Adjusted EBITDA?

Cannara Biotech Q2 FY23 Revenue Grows 76% YoY To $9.6M, Here Are The Details

Cannara Biotech Q3 FY23 Net Revenue Grows 57% YoY, What About Adjusted EBITDA?

Cannara Biotech Q2 FY23 Revenue Grows 76% YoY To $9.6M, Here Are The Details

Cannara Biotech Q4 Revenue Grows 84% YoY To $8.9M

Cannara Biotech Enters Into The British Columbia Cannabis Market And Launches New Products

Cannara Biotech Q4 Revenue Grows 84% YoY To $8.9M

Cannara Biotech Enters Into The British Columbia Cannabis Market And Launches New Products

Cannara Biotech Revenue Grows 41% YoY, Here Are The Details

Cannara Biotech Revenues Grew 229% To $7.4M In Q2 2022 YoY

Zohar Krivorot Recent News

Cannara Biotech Shares Surge On 983% QoQ Revenue Growth, Positive Adjusted EBITDA

Vertically integrated cannabis company Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) released its fourth quarter and fiscal year 2021 financial and operating results on Wednesday with quarterly revenue of CA$6.5 million ($5.12 million), up by 983.33% from CA$600,000 in t

Cannara Biotech Cannabis Co. Slightly Beats Estimates, Posts $7.2M In Q3 2021 Revenue

Vertically integrated cannabis company Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) reported Wednesday that it had generated $7.2 million in the third quarter of 2021,

Cannara Biotech Cannabis Co. Expects To Post $7.1M In Q3 Revenue After Successful Market Launch In Quebec

Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) disclosed Monday it expects to generate roughly $7.1 million in the third quarter of 2021. That's a $5.1 million revenue growth compared to the prior period.

Cannara Biotech To Buy Remaining Stake In shopCBD.com

Vertically integrated cannabis company Cannara Biotech Inc.